Меню
Идёт набор NCT06467474

Psychoeducational Group for Depression

Без фазы С лечением Major Depressive Disorder (MDD

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: PEG-D program, TAU.
Кому может быть актуально
Состояния в реестре: Major Depressive Disorder (MDD. Базовые параметры: 18 лет — 59 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Бразилия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Psychoeducation for Major Depressive Disorder: Development and Evaluation of Effectiveness

Обзор

The study aims to investigate the efficacy of a psychoeducational program as an adjunctive treatment for depression. The study will involve 338 patients diagnosed with Major Depressive Disorder (MDD) of moderate severity. Participants will be randomly assigned to receive either Treatment as usual (TAU) alone or TAU plus the psychoeducational program. The program consists of six weekly group sessions covering information and techniques for coping with depression. Primary outcomes include a reduction in depressive symptoms measured by the Beck Depression Inventory-II (BDI-II) and increased knowledge of depression. Secondary outcomes include improvements in functionality and quality of life. The study aims to provide insights into the effectiveness of psychoeducation in improving outcomes for individuals with depression

Вмешательства

  • Поведенческое PEG-D program
    PEG-D will be carried out in person, open format, for six consecutive weeks lasting 90 minutes each. An approximate group of 6 to 10 participants will be led by a team of experienced psychologists and psychiatrists. Each group will have a main therapist and a co-therapist to ensure effective support and guidance for participants. Before the start of the group, participants received a booklet containing the content of the sessions.
  • Препарат TAU
    The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\'s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the

Первичные конечные точки

  • Knowledge level [Срок оценки: Time: baseline, post 6 weeks and 12 months.]
  • Depressive levels [Срок оценки: Baseline, post 6 weeks, 3, 6 and 12 months.]
Вторичные конечные точки (3)
  • Depressive Thoughts [Срок оценки: Baseline, post 6 weeks, 3, 6 and 12 months]
  • Avoidance behaviors [Срок оценки: Baseline, post 6 weeks, 3, 6 and 12 months.]
  • Functionality [Срок оценки: Baseline, post 6 weeks, 3, 6 and 12 months.]

Критерии участия

Inclusion:

  • Both sexes;
  • Ages between 18 and 65 years old;
  • Diagnosis of Major Depressive Disorder (MDD) made by a clinician according to Diagnostic Statistical Manual criteria-5-Text Revised (DSM-5-TR)
  • Patients with Hamilton Depressive Rating Scale-17 items (HDRS-17) scores 14-23;
  • Informed and signed consent form.

Exclusion:

  • Unstable serious clinical or neurological diseases;
  • Postpartum depression or other types of depressive disorders (disruptive mood dysregulation disorder, pre-menstrual, substance/medication-induced depressive disorder, depressive disorder due to another medical condition, another disorder specified depressive disorder and unspecified depressive disorder);
  • Other psychiatric disorders;
  • Patients with active psychotic symptoms;
  • Suicidality risks
  • Patients already undergoing any other psychological treatment for MDD;

Discontinuation:

  • More than two absences during treatment;
  • Those who miss more than two sessions/consultations, whether medical treatment or the psychoeducational program;
  • Non-response to the use of Sertraline over the initial eight weeks; Presence of hypomanic symptoms at any time during treatment (Young \<7)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Перекрёстный дизайн
Маскирование
Простое слепое
Основная цель
Лечение

Центры проведения

Бразилия · 1 центр
  • Institute of Psychiatry - Faculty of Medicine from University of Sao Paulo — São Paulo

Публикации

  • Carneiro AM, Silva SLT, Fernandes FDS, Barretto JR, de Brito TR, Moreno LH, Pimentel FC, Jorge BA, Dos Santos LA, Fernandes Ramos MR, Moreno RA. Psychoeducation Group for Depression (PEG-D): Study protocol for a prospective, randomized, single-blind, crossover trial. PLoS One. 2025 Aug 8;20(8):e0329006. doi: 10.1371/journal.pone.0329006. eCollection 2025. PMID 40779501

Идентификаторы

NCT: NCT06467474 · 76212623.1.0000.0068

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗